Crinetics Pharmaceuticals Inc R&D Day Transcript - Thomson StreetEvents

Crinetics Pharmaceuticals Inc R&D Day Transcript

Crinetics Pharmaceuticals Inc R&D Day Transcript - Thomson StreetEvents
Crinetics Pharmaceuticals Inc R&D Day Transcript
Published Jun 26, 2025
31 pages (23828 words) — Published Jun 26, 2025
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of CRNX.OQ corporate analyst meeting

  
Brief Excerpt:

...Good morning, everyone. Welcome to Crinetic's first R&D Day. For those of you joining in person, I'm so glad the weather has calmed down a little bit, so you're not swelltering on your way here. And for those of you joining virtually, welcome you to the webcast. So we'll be making forward-looking statements today. So I'll pause for a few seconds on the slide if we absorb all of the fine tech print. Let's see. So now the speakers today, you all know Scott Struthers and Dr. Stephen Betz, the Co-Founders and CEO and Chief Scientific Officer. But I think the real superstars of today's presentation are global product leaders, our GPLs. So the GPLs are the CEO of their molecule, and they oversee the process from, a chaperone the molecule from discovery all the way through clinical development to commercialization. So really responsible for the strategy and execution and know everything there is to know about the molecule. Today, we have Rick Grimes here covering TSH and Stacey Harte for the NDC-9682....

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Crinetics Pharmaceuticals Inc
Ticker
CRNX.OQ
Time
1:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Douglas Tsao - H.C. Wainwright & Co. - Analyst : Doug Tsao, H.C. Wainwright. I guess on the TSH antagonist program, obviously, one of the attractive attributes of the molecule is its ability to potentially address both grade disease as well as Ted. I'm just curious how you're thinking at this point in terms of the development program and the sort of maybe is one of those indications sort of prioritized over the other. And I know you sort of alluded and in conversations with Scott in the past, you sort of alluded to the potential value being the opportunity to prevent the development of Ted. And I'm just curious if you have thoughts in terms of the practicality of running a clinical development program that would be able to demonstrate that?

Table Of Contents

Crinetics Pharmaceuticals Inc Corporate Update Call Transcript – 2026-01-05 – US$ 106.00 – Edited Transcript of CRNX.OQ conference call or presentation 5-Jan-26 1:30pm GMT

Crinetics Pharmaceuticals Inc Q3 2025 Earnings Call Transcript – 2025-11-06 – US$ 54.00 – Edited Transcript of CRNX.OQ earnings conference call or presentation 6-Nov-25 9:30pm GMT

Crinetics Pharmaceuticals Inc Palsonify FDA Approval Call Transcript – 2025-09-25 – US$ 54.00 – Edited Transcript of CRNX.OQ conference call or presentation 25-Sep-25 10:00pm GMT

Crinetics Pharmaceuticals Inc Q2 2025 Earnings Call Transcript – 2025-08-07 – US$ 54.00 – Edited Transcript of CRNX.OQ earnings conference call or presentation 7-Aug-25 8:30pm GMT

Crinetics Pharmaceuticals Inc Q1 2025 Earnings Call Transcript – 2025-05-08 – US$ 54.00 – Edited Transcript of CRNX.OQ earnings conference call or presentation 8-May-25 8:30pm GMT

Crinetics Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript – 2025-03-03 – US$ 54.00 – Edited Transcript of CRNX.OQ presentation 3-Mar-25 4:10pm GMT

Crinetics Pharmaceuticals Inc Q4 2024 Earnings Call Transcript – 2025-02-27 – US$ 54.00 – Edited Transcript of CRNX.OQ earnings conference call or presentation 27-Feb-25 9:30pm GMT

Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript – 2025-01-15 – US$ 54.00 – Edited Transcript of CRNX.OQ presentation 15-Jan-25 12:30am GMT

Crinetics Pharmaceuticals Inc Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia Call Transcript – 2025-01-10 – US$ 54.00 – Edited Transcript of CRNX.OQ conference call or presentation 10-Jan-25 1:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Crinetics Pharmaceuticals Inc R&D Day Transcript" Jun 26, 2025. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Crinetics-Pharmaceuticals-Inc-R-D-Day-T16363749>
  
APA:
Thomson StreetEvents. (2025). Crinetics Pharmaceuticals Inc R&D Day Transcript Jun 26, 2025. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Crinetics-Pharmaceuticals-Inc-R-D-Day-T16363749>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.